iBio, Inc.
NASDAQ:IBIOBiotechnology
+$0.00 today
- Market cap
- $59.75M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.81M
IBIO Tax Payables
Taxes owed to authorities that have not yet been paid.
iBio, Inc.NASDAQ: IBIO
Tax Payables · Q4 FY2026 · quarter ended Jun 2026
Tax payables remains negative
Q4 FY2026 tax payables was $0, compared with $0 a year earlier.
Context
- Tax payables amounted to 0.0% of total assets at the end of Q4 FY2026, unchanged from a year earlier.
- Tax payables increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Payables history
USD · from the balance sheet
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Payables | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 0 | — |
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | -100.0% |
| FY2023 | 2023-06-30 | 268K | -5.6% |
| FY2022 | 2022-06-30 | 284K | — |
Tax Payables vs competitors
How IBIO compares with its peers on the latest reported figures
- IBIO's Jun 2026 tax payables of $0 is the highest of the 4 companies compared; the peer median is $0.
- Tax payables amounts to 0.0% of total assets for IBIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IBIO) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 22.68M | 7.33M | 14.21M | 8.58M | 56.4M |
| Short-term Investments | 10.85M | 0 | 0 | 0 | 31.64M |
| Net Receivables | 6.1M | 204K | 713K | 105K | 1.1M |
| Inventory | 3.9M | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 18.73M | 749K | 1.03M | 3.08M |
| Total Current Assets | 45.07M | 26.26M | 15.67M | 9.72M | 92.22M |
| Property, Plant & Equipment (Net) | 41.76M | 7.55M | 6.37M | 5.28M | 4.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.85M | 5.39M | 5.37M | 6.85M | 1.83M |
| Long-term Investments | 7.63M | 1.96M | 1.3M | 1.31M | 228K |
| Tax Assets | (7.63M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.73M | 50K | 26K | 26K | 83K |
| Total Non-current Assets | 54.34M | 14.95M | 13.06M | 13.46M | 6.89M |
| Total Assets | 99.41M | 41.21M | 28.73M | 23.19M | 99.11M |
| Account Payables | 4.26M | 1.85M | 358K | 2.19M | 4.42M |
| Short-term Debt | 22.16M | 13.6M | 218K | 766K | 0 |
| Tax Payables | 284K | 268K | 0 | 0 | 0 |
| Deferred Revenue | 100K | 0 | 200K | 1.2M | 0 |
| Other Current Liabilities | 754K | 2.52M | 761K | 876K | 6.78M |
| Total Current Liabilities | 30.44M | 21.58M | 3.84M | 6.11M | 11.75M |
| Long-term Debt | 0 | 0 | 766K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.97M | 768K | 63K | 0 | 0 |
| Total Non-current Liabilities | 5.49M | 4.24M | 3.57M | 2.2M | 1.65M |
| Total Liabilities | 35.92M | 25.83M | 7.41M | 8.31M | 13.4M |
| Common Stock | 9K | 20K | 9K | 19K | 56K |
| Retained Earnings | (223.93M) | (288.94M) | (313.85M) | (332.22M) | (365.27M) |
| Accumulated OCI | (213K) | 0 | 0 | 0 | (45K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 63.49M | 15.38M | 21.32M | 14.88M | 85.71M |
| Total Debt | 25.77M | 17.07M | 4.46M | 3.51M | 2.2M |
| Net Debt | 3.09M | 9.75M | (9.75M) | (5.07M) | (54.2M) |
iBio, Inc.
NASDAQ:IBIO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.